Peer into the future of drug development with this episode of #AViewOn Drug Bioavailability Enhancement, exploring how PBPK modeling enhances drug bioavailability and paves the way for personalized medicine. Join experts Deanna Mudie and John DiBella in this discussion on making medications safer and more effective.

Dive into the world of targeted capsules with Vincent Jannin from Lonza and explore how these advanced drug delivery systems are transforming patient care and offering new horizons in medicine.

Embark on a microscopic journey into particle identification — the unsung hero of phar-maceutical safety — and uncover how this vital process shields us from unseen threats in every single medication we take.

In this summary episode, A View On host Martina Ribar Hestericova shares a secret and goes over a selection of the best ideas from season three so far.

"A View On: CAR-T Cell Therapies" featuring Tamara Laskowski, Senior Director of Clinical Development in Personalized Medicine at Lonza, and Aya Jakobovits, CEO of Adicet Bio. Dive into the world of CAR-T cells, their therapeutic potential, and the future of cancer treatments.

Lonza experts Selene Araya and Charles Johnson discuss the manufacturing process, trends, and future of highly potent compounds (HPAPIs). They highlight Lonza's facilities and expertise in producing HPAPIs across various technologies and scales, ensuring advanced containment and addressing bioavailability challenges.

Ian Thomson from Ypsomed and Roman Mathias from Lonza discuss the market trends in injectable delivery devices, their manufacturing process, and their future in sustainable pharma. Injectable devices offer various benefits, including improved convenience, accuracy, and safety, allowing for precise dosing while reducing the need for hospital visits.     

Scaling Up Cell and Gene Therapies: Automation Is the Next Step   In this episode, we take a deep dive into manufacturing cell and gene therapies with Lonza expert Behnam Ahmadian Baghbaderani, executive director of Cell and Gene Therapy Process Development.   Cell and gene therapies have the potential to revolutionize the treatment of rare genetic diseases, cancer, and neurodegenerative disorders. These therapies involve extracting cells or genetic material from a patient or donor, altering...

What If the Jab Were a Puff? A Look at Drug Delivery to the Lungs In this episode we explore the advantages of using inhalers for drug delivery with Lonza experts Kim Shepard and Matt Ferguson.

Safe Jabs Thanks to Horseshoe Crabs: Making Sure Your Injection is Free of Endotoxins Allen Burgenson, Lonza’s expert for all things testing, speaks to us about the dangers of endotoxin contamination and the future of non-animal testing for it. “Before testing for endotoxins in the 1940s, a physician literally had to gauge the risk to your life because of something called injection fever,” explains Allen Burgenson. Luckily, we’ve come a long way since then. Thanks to advanced testing methods,...

We are back! And in the first episode of our new season, we explore growing cells for therapeutic purposes with Lonza specialists Alexis Bossie, Director of Media R&D, and Tariq Haq, Senior Director of Global Media Marketing. Listen to learn more about the development of cell culture media for growing cells.

In the latest episode, the podcast host, Lonza’s Martina Ribar Hestericová, recaps the highlights from this season and looks forward to later this year for what is coming up in the next season.

Listen to the conversation between A View On host Martina Hestericová and two world specialists about the present and future applications of AI and Machine Learning in the pharmaceutical industry. Dr. Loubna Bouarfa, CEO of OKRA.ai, and Stephan Rosenberger, Lonza’s Head of Digital Transformation, discuss how AI is currently transforming the pharma industry.

Where There’s A Risk, There’s A Way: De-risking Drug Development at the Earliest Stages Lonza’s wide array of analytical tools and professional experience create a go-to solution for small biotechs looking to decrease risk in their drug development process. An evolving toolbox of technology and advanced scientific knowledge is fueling the growth of a wide range of next-generation drugs in today’s pipelines. These novel but complex products, while offering the ability to treat previously...

Listen to the conversation between A View On host Martina Hestericová and Ljiljana Palangetic, Lonza’s Associate Director of Hard Capsules R&D, about the challenges and solutions in current capsule manufacturing.

Iwan Bertholjotti and Lawrence Bonnafoux from Lonza give an insider look at how antibody-drug conjugates make it from development to commercialization and how they are already benefiting patients worldwide.

Listen to Martina Hestericová’s conversation with Sriram Sathyanarayanan and Linda Bain as they discuss the advantages of exosome treatments, how they are developed and why the company’s early manufacturing strategy is paying off.

In this reposted episode from December 2020, we’re exploring how a better understanding of exosomes is leading to new treatments and diagnostic technologies with Uwe Gottschalk.  Listen to our special, in-house episode of the podcast ”A View On” and tune in next time as we are exploring the manufacturing challenges of exosome-based therapies with Codiak Biosciences.

Yvette Stallwood, head of Lonza’s Early Development Services, talks about patient safety and other advantages of early testing for immunogenicity in the drug development pipeline.

Professor Eran Elinav from the Weizmann Institute of Science discusses how the interaction between the microbiome and its host is transforming personalized medicine.

Bridging Business and Biotechnology: Kodiak Sciences Is Increasing Treatment Efficacy for Retinal Diseases Victor Perlroth, MD, the Chairman and CEO of Kodiak Sciences, discusses how the company’s ABC platform medicines are designed to treat the leading causes of blindness.

Safe Jabs Thanks to Horseshoe Crabs: Making Sure Your Injection is Free of Endotoxins Allen Burgenson, Lonza’s expert for all things testing, speaks to us about the dangers of endotoxin contamination and the future of non-animal testing for it.

Chairman and founder of PsiVac, Prof. Ghassan Alusi, and the chief operating officer, Imad Mardini, discuss how the company’s proprietary oncolytic virus platform offers new hope for cancer patients.

It’s the season finale for A View On, the Lonza podcast. Over the past 12 months of our initial run, we have brought you a series of conversations exploring the new pharma and biotechnology trends. We spoke to Lonza and the industry experts and discussed exciting topics, such as exosomes, stem cells, drug product testing, bioprinting, and much more. In the latest episode, the podcast host, Lonza’s Martina Ribar Hestericová, recaps the highlights from this season and looks forward to later...